Rome, March 22nd, 2018 On March 22nd, Luigi Visani, CEO of Exom Group, will be among the speakers of the congress organized by the Italian Federation of the Internal Medicine Hospital Executives’ Associations (FADOI,) that will be dealing with the no-profit...
On November 14th, Luigi Visani, CEO of Exom Group, has been among the speakers of the seminar organized by the Polish Association of GCPs Professionals entitled “The e-solutions in medicine, such as eHR and eICF, will revolutionize clinical research ? “ and made a...
Exom starts an observational prospective multicenter study to assess the long-term effectiveness and tolerability of a new PCSK9-I inhibitor in the real life clinical practice, in a severe hypercholesterolemic population resistant to full dosage statins. The study...
The first electronic Informed Consent fully combined with the eTMF Exom Group, the Human Digital CRO, has launched Genius ENGAGE™, the industry’s first ever electronic Informed Consent solution whose digital workflow is fully combined with the eTMF, and integrated...
For Efficient Document Management and Real-time Visibility Exom’s deployment of the eTMF has been selected by Veeva Inc. as a case study showing how the cloud-based Veeva Vault eTMF streamlines trial processes and achieve greater efficiency. Veeva Vault eTMF is...
Global Health & Pharma Excellence AwardsAward Winner 2022
Exom is proud to announce that Global Health & Pharma has awarded us the 2022 Global Excellence Award as "Most innovative Full-Service CRO - 2022" for our pioneering, cutting-edge use of technology in clinical trials to support study stakeholders.
